This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Stock Reports for NVIDIA, Philip Morris & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Philip Morris International Inc. (PM) and Sanofi (SNY).
Medtronic (MDT) Gets Health Canada License for Hugo RAS System
by Zacks Equity Research
The receipt of the Health Canada license for Medtronic's (MDT) Hugo RAS System is likely to enhance accessibility to robotic-assisted surgery in Canada.
The Zacks Analyst Blog Highlights: Microsoft, NVIDIA, Medtronic, The Progressive and Vertex Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, NVIDIA, Medtronic, The Progressive and Vertex Pharma
Top Stock Reports for Microsoft, NVIDIA & Medtronic
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), NVIDIA Corporation (NVDA), and Medtronic plc (MDT).
Medtronic (MDT) Gets Health Canada License for GI Genius Module
by Zacks Equity Research
Medtronic Canada ULC, a subsidiary of Medtronic (MDT), receives Health Canada license for the GI Genius module that aids in colorectal cancer screening.
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Chevron, Medtronic and Danaher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Chevron, Medtronic and Danaher
Top Stock Reports for Microsoft, JPMorgan Chase & Chevron
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), JPMorgan Chase & Co. (JPM) and Chevron Corporation (CVX).
Medtronic's (MDT) Q2 Earnings Beat, Revenues Lag Estimates
by Urmimala Biswas
Medtronic (MDT) cuts revenue growth guidance for the full year on the projection of a severe pandemic impact to continue through the rest of the year.
Medtronic (MDT) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 2.33% and 1.18%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
by Zacks Equity Research
Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
Medtronic (MDT) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Through Medtronic's (MDT) second-quarter months, the market continues return to normalcy on mass vaccine rollouts in spite of COVID-19 resurgence.
Medtronic (MDT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic's (MDT) PillCam SB3 System Gets 510 (k) Clearance
by Zacks Equity Research
Medtronic's (MDT) PillCam SB3 System provides a convenient option for a contactless procedure and helps ensure that patients can access care promptly.
The Zacks Analyst Blog Highlights: Microsoft, Berkshire Hathaway, Oracle, Medtronic and Simon Property Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Berkshire Hathaway, Oracle, Medtronic and Simon Property Group
Top Research Reports for Microsoft, Berkshire Hathaway & Oracle
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Berkshire Hathaway Inc. (BRK.B), and Oracle Corporation (ORCL).
Medtronic (MDT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $122.29, marking a -0.59% move from the previous day.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $121.18 in the latest trading session, marking a -0.1% move from the prior day.
Intersect ENT (XENT) Q3 Loss Widens, Sell-Off Process On Track
by Zacks Equity Research
An increase in Intersect ENT's (XENT) operating costs puts pressure on its Q3 bottom line.
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $121.27, marking a -1% move from the previous day.
The Zacks Analyst Blog Highlights: Disney, Intel, Medtronic, Target and Deere
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Disney, Intel, Medtronic, Target and Deere
Q3 Earnings Season Scorecard and Analyst Reports for Disney, Intel & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Intel Corporation (INTC), and Medtronic plc (MDT).
3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.
Boston Scientific's (BSX) Ranger DCB Trial Outcome Favorable
by Zacks Equity Research
Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.
Medtronic (MDT) Sees Business Recovery Despite Volume Pressure
by Zacks Equity Research
According to Medtronic (MDT), healthcare systems are better prepared as vaccination rates continue to increase.